GL-3, plasma-994

Test info

  
GL-3, plasma
  
994
  
LAB994
  
Fabrazyme biomarker
Fabry disease biomarker
  

Enzyme replacement therapy with Fabryzme results in a rapid and sustained decrease in plasma GL-3 levels and most patients. Periodic testing for GL-3 levels in plasma is recommended as part of the minimal schedule of assessments from the Fabry Registry prior to the start of treatment come every three months for the first 18 months of treatment and then every six months.

Specimen

  
Plasma
  
  
1 mL
  
0.4 mL
  
  • Spin
  • Separate plasma into Labcorp transport vial
  • Freeze
  

Frozen (preferred) - 3 months

Freeze thaw cycles x 6

  

Clotted or severely hemolyzed plasma samples

Performance

  
Labcorp (504662) R-LC
  
One day per week
  
14 days
  

LC/MS

Clinical and Interpretive info

  

ug/mL

Billing

  
82542

Tracking

  
08/10/2022
  
08/12/2022